lilly retatrutide trial Eli Lilly's tirzepatide showed positive results in late-stage as treatment for heart failure Today, we shared new data

NICE guidelines (NG28) support the use of GLP-1 receptor agonists for type 2 diabetes when glycaemic targets are not achieved with other therapies, and for weight management in specific circumstances (TA875 for Wegovy, TA664 for Saxenda)

Understanding how these medications work helps clarify their role

placebo showing superiority in incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke

Experimenting with timing can help you find what works best for your schedule and symptom pattern

Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction

Subscribe to our emails Search Our Blog Recent Posts One shake a day